Irinotecan Eugia (Irinotecan Hydrochloride Trihydrate)

Irinotecan is converted inside cells to the active metabolite SN‑38, which binds to the DNA‑topoisomerase I complex. By preventing the religation of single‑strand DNA breaks, SN‑38 causes accumulation of DNA damage, leading to apoptosis of rapidly dividing cancer cells.

The dose of Irinotecan Eugia is individualized by the prescribing oncologist based on factors such as the patient’s body surface area, disease stage, and treatment protocol. Specific dosing regimens are not disclosed publicly and should be determined by a qualified healthcare professional.

There is limited clinical data on the use of Irinotecan during pregnancy or lactation. Because it may cause fetal harm and is excreted in breast milk, it is generally contraindicated in pregnant or breastfeeding women unless the potential benefit justifies the risk.

To place an order, submit an enquiry on the Irinotecan Eugia product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where applicable) and necessary import documentation.

The closest alternative within the same class is topotecan, another topoisomerase I inhibitor. Irinotecan generally has a broader indication spectrum, especially for colorectal cancer, and its toxicity profile differs, with more pronounced diarrhea and neutropenia, whereas topotecan is often associated with greater myelosuppression.

Irinotecan Eugia should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct light, and extreme temperature fluctuations. Follow standard aseptic handling procedures for injectable medicines.

Irinotecan is given by intravenous infusion, typically over 30 to 90 minutes depending on the protocol. The infusion is performed in a clinical setting by qualified healthcare personnel, with monitoring for infusion‑related reactions and supportive care as needed.

The most serious adverse events include severe neutropenia (especially febrile neutropenia), life‑threatening diarrhea or colitis, hepatic toxicity, and rare allergic reactions. Prompt medical attention is required if fever, persistent diarrhea, jaundice, or signs of an allergic response develop.

Patients with known hypersensitivity to Irinotecan or any of its excipients, those with severe hepatic impairment, and individuals with uncontrolled infections should avoid the drug. Caution is also advised for patients with pre‑existing bowel disorders or significant bone‑marrow suppression.